Davita (NYSE:DVA) was downgraded by analysts at Raymond James from an “outperform” rating to a “market perform” rating in a research note issued on Thursday, MarketBeat Ratings reports.

Several other equities analysts have also issued reports on the company. William Blair lowered Davita from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 11th. TheStreet upgraded Davita from a “c+” rating to a “b-” rating in a research note on Wednesday, July 24th. Robert W. Baird lowered Davita from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $70.00 to $65.00 in a research note on Friday, July 26th. UBS Group lowered their price objective on Davita from $61.00 to $60.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Finally, ValuEngine upgraded Davita from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Nine investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $64.81.

DVA traded up $0.66 on Thursday, hitting $69.85. 2,446,213 shares of the stock traded hands, compared to its average volume of 2,127,695. Davita has a 52 week low of $43.40 and a 52 week high of $70.51. The company has a current ratio of 1.12, a quick ratio of 1.10 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $10.01 billion, a PE ratio of 19.57, a P/E/G ratio of 0.62 and a beta of 1.59. The business has a fifty day moving average price of $58.51 and a two-hundred day moving average price of $55.70.

Davita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.29. Davita had a return on equity of 18.03% and a net margin of 3.68%. The firm had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same period in the previous year, the company posted $0.56 earnings per share. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. On average, equities research analysts forecast that Davita will post 5.19 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Davita by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 13,652,940 shares of the company’s stock valued at $768,114,000 after purchasing an additional 64,415 shares during the period. Par Capital Management Inc. grew its stake in shares of Davita by 40.6% in the 2nd quarter. Par Capital Management Inc. now owns 4,159,000 shares of the company’s stock valued at $233,985,000 after purchasing an additional 1,201,300 shares during the period. Invesco Ltd. grew its stake in shares of Davita by 56.2% in the 2nd quarter. Invesco Ltd. now owns 3,662,685 shares of the company’s stock valued at $206,063,000 after purchasing an additional 1,317,725 shares during the period. Viking Global Investors LP grew its stake in shares of Davita by 5.5% in the 2nd quarter. Viking Global Investors LP now owns 2,907,034 shares of the company’s stock valued at $163,550,000 after purchasing an additional 151,529 shares during the period. Finally, Camber Capital Management LP grew its position in Davita by 33.3% during the 2nd quarter. Camber Capital Management LP now owns 2,000,000 shares of the company’s stock worth $112,520,000 after acquiring an additional 500,000 shares during the last quarter. Institutional investors own 91.00% of the company’s stock.

Davita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also: What is a good dividend yield?

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.